NO331183B1 - Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer - Google Patents

Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer

Info

Publication number
NO331183B1
NO331183B1 NO20093217A NO20093217A NO331183B1 NO 331183 B1 NO331183 B1 NO 331183B1 NO 20093217 A NO20093217 A NO 20093217A NO 20093217 A NO20093217 A NO 20093217A NO 331183 B1 NO331183 B1 NO 331183B1
Authority
NO
Norway
Prior art keywords
halochondrine
analogue
pharmaceutical
pharmaceutically acceptable
acceptable carrier
Prior art date
Application number
NO20093217A
Other languages
English (en)
Other versions
NO20093217L (no
Inventor
Wanjun Zheng
Bruce A Littlefield
Boris M Seletsky
Murray J Towle
Melvin J Yu
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331183(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20093217L publication Critical patent/NO20093217L/no
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO331183B1 publication Critical patent/NO331183B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet halikondrinanaloger som har farmasøytisk aktivitet, så som anti-kreft eller anti-mitotisk (mitoseblokkerende) aktivitet, og fremgangsmåter for å identifisere midler som induserer en vedvarende mitotisk blokkering i en celle etter transient eksponering av cellen mot midlene.
NO20093217A 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer NO331183B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17

Publications (2)

Publication Number Publication Date
NO20093217L NO20093217L (no) 2001-02-15
NO331183B1 true NO331183B1 (no) 2011-10-24

Family

ID=22219026

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20006316A NO328280B1 (no) 1998-06-17 2000-12-12 Makrocykliske analoger
NO20093217A NO331183B1 (no) 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
NO2011018C NO2011018I1 (no) 1998-06-17 2011-09-16 Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no) 1998-06-17 2011-12-14 Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no) 1998-06-17 2022-06-03 Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20006316A NO328280B1 (no) 1998-06-17 2000-12-12 Makrocykliske analoger

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO2011018C NO2011018I1 (no) 1998-06-17 2011-09-16 Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no) 1998-06-17 2011-12-14 Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no) 1998-06-17 2022-06-03 Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Country Status (23)

Country Link
US (4) US6214865B1 (no)
EP (4) EP2272840B1 (no)
JP (1) JP4454151B2 (no)
KR (1) KR100798600B1 (no)
CN (1) CN1216051C (no)
AT (1) ATE502932T1 (no)
AU (1) AU762998B2 (no)
BE (1) BE2011C028I2 (no)
BR (1) BRPI9911326B8 (no)
CA (3) CA2755266C (no)
CY (2) CY1111516T1 (no)
DE (2) DE122011100031I1 (no)
DK (1) DK1087960T3 (no)
FR (1) FR11C0038I2 (no)
HK (1) HK1035534A1 (no)
HU (1) HU227912B1 (no)
IL (1) IL139960A0 (no)
LU (1) LU91854I2 (no)
NO (5) NO328280B1 (no)
NZ (1) NZ508597A (no)
PT (1) PT1087960E (no)
WO (1) WO1999065894A1 (no)
ZA (1) ZA200007159B (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
EP2272840B1 (en) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
KR101208266B1 (ko) 2002-03-22 2012-12-05 에자이 알앤드디 매니지먼트 가부시키가이샤 헤미아스텔린 유도체 및 이의 용도
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
JP2007500240A (ja) * 2003-05-29 2007-01-11 アボット・ラボラトリーズ Ａｂｔ−７５１による持続投与レジメン
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
PL2522663T3 (pl) * 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
CN104311571B (zh) * 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
SG189739A1 (en) * 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
RS55148B1 (sr) 2009-03-30 2016-12-30 Eisai R&D Man Co Ltd Smeša lipozoma
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
JP5556811B2 (ja) * 2009-04-14 2014-07-23 日産化学工業株式会社 テトラヒドロピラン化合物の製造方法
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体
SG193489A1 (en) 2011-03-18 2013-10-30 Eisai R&D Man Co Ltd Methods and compositions for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
AU2012363334B2 (en) * 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
US20140163095A1 (en) 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
TW201514159A (zh) 2013-05-15 2015-04-16 Alphora Res Inc ３-（（２ｓ，５ｓ）-４-亞甲基-５-（３-氧代丙基）四氫呋喃-２-基）丙醇衍生物、其製備及對其有用的中間體
CA2915005C (en) 2013-06-26 2021-12-28 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
EP3016957A4 (en) * 2013-07-03 2016-11-30 Alphora Res Inc SYNTHETIC METHOD FOR THE PRODUCTION OF CYCLIC C1-KETO ANALOGUE OF HALICHONDRIN B AND USEFUL INTERMEDIATE PRODUCTS, INCLUDING INTERMEDIATE PRODUCTS WITH -SO2- (P-TOLYL) GROUPS
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
ES2787603T3 (es) 2013-11-04 2020-10-16 Eisai R&D Man Co Ltd Reacciones de macrociclación y productos intermedios útiles en la síntesis de análogos de halicondrina B
JP6443812B2 (ja) 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類縁体の合成に有用な方法
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
EP3148526B1 (en) * 2014-05-28 2021-01-06 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
BR112017002827B1 (pt) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
MX2017010474A (es) 2015-02-25 2017-11-28 Eisai R&D Man Co Ltd Metodo para suprimir el amargor de un derivado de quinoleina.
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
SG11201706872SA (en) * 2015-03-04 2017-09-28 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating cancer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
WO2016179607A1 (en) * 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
EP3413887B1 (en) 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2017203459A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN109641917B (zh) 2016-06-30 2022-06-14 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
AU2017342462A1 (en) 2016-10-14 2019-05-02 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
KR20190084065A (ko) 2016-11-23 2019-07-15 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그 중간체의 제조방법
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
WO2018124847A1 (ko) 2017-01-02 2018-07-05 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
PT3606928T (pt) 2017-04-05 2022-12-05 Harvard College Composto macrocíclico e utilizações deste
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
JP6967811B2 (ja) * 2017-11-09 2021-11-17 ヨンスン ファイン ケミカル カンパニー，リミテッド エリブリンメシル酸塩の製造中間体及びその製造方法
EP4403560A2 (en) 2017-11-15 2024-07-24 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (en) 2017-11-21 2019-05-31 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
IL275729B2 (en) 2018-01-03 2023-09-01 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of helicondrin macrolides and their analogs
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020016847A2 (en) * 2018-07-20 2020-01-23 Dr. Reddy’S Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
WO2020075027A1 (en) * 2018-10-09 2020-04-16 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US20220333139A1 (en) 2019-06-21 2022-10-20 Council Of Scientific And Industrial Research A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
PE20230467A1 (es) 2019-11-07 2023-03-14 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
CA3168654A1 (en) * 2020-01-22 2021-07-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
CN118356507A (zh) * 2023-01-17 2024-07-19 成都百利多特生物药业有限责任公司 一种艾日布林类药物的偶联物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2272840B1 (en) * 1998-06-17 2012-08-22 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN104311571B (zh) * 2007-10-03 2019-07-02 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
SG189739A1 (en) * 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
JP5800834B2 (ja) * 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体の合成において有用なフロ［３，２−ｂ］ピラン誘導体

Also Published As

Publication number Publication date
CN1312804A (zh) 2001-09-12
BR9911326B1 (pt) 2015-01-06
KR20010083050A (ko) 2001-08-31
BRPI9911326B8 (pt) 2021-05-25
DE122011100031I1 (de) 2011-12-15
CA2632433C (en) 2012-02-07
WO1999065894A1 (en) 1999-12-23
BR9911326A (pt) 2001-04-03
KR100798600B1 (ko) 2008-01-28
CA2755266A1 (en) 1999-12-23
CA2632433A1 (en) 1999-12-23
US6469182B1 (en) 2002-10-22
JP4454151B2 (ja) 2010-04-21
AU762998B2 (en) 2003-07-10
IL139960A0 (en) 2002-02-10
EP2272839B1 (en) 2012-08-22
HK1035534A1 (en) 2001-11-30
EP2272840B1 (en) 2012-08-22
RU2245335C2 (ru) 2005-01-27
NO2011026I1 (no) 2012-01-09
NO2011026I2 (no) 2012-06-11
CY2011010I2 (el) 2014-04-09
NO20006316L (no) 2001-02-15
CA2335300A1 (en) 1999-12-23
BE2011C028I2 (en) 2018-08-24
DK1087960T3 (da) 2011-06-14
PT1087960E (pt) 2011-06-17
JP2002518384A (ja) 2002-06-25
CY2011010I1 (el) 2014-04-09
ZA200007159B (en) 2001-12-04
EP1087960A4 (en) 2004-12-01
LU91854I2 (fr) 2011-10-17
US8148554B2 (en) 2012-04-03
CY1111516T1 (el) 2014-04-09
AU4573999A (en) 2000-01-05
DE69943296D1 (de) 2011-05-05
NZ508597A (en) 2004-01-30
NO328280B1 (no) 2010-01-25
CA2335300C (en) 2008-10-07
US20110172446A1 (en) 2011-07-14
US6214865B1 (en) 2001-04-10
HUP0103357A3 (en) 2002-10-28
AU762998C (en) 2000-01-05
CN1216051C (zh) 2005-08-24
EP2277873A1 (en) 2011-01-26
NO2011018I1 (no) 2011-09-26
HU227912B1 (en) 2012-05-29
HUP0103357A2 (hu) 2002-01-28
ATE502932T1 (de) 2011-04-15
NO20006316D0 (no) 2000-12-12
EP2277873B1 (en) 2012-05-30
FR11C0038I2 (fr) 2013-01-11
EP1087960A1 (en) 2001-04-04
FR11C0038I1 (fr) 2011-10-14
EP2272839A1 (en) 2011-01-12
CA2755266C (en) 2014-08-12
NO20093217L (no) 2001-02-15
EP1087960B1 (en) 2011-03-23
US6365759B1 (en) 2002-04-02
EP2272840A1 (en) 2011-01-12
NO2022019I1 (no) 2022-06-03

Similar Documents

Publication Publication Date Title
NO331183B1 (no) Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
BR0209948A (pt) Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos
GB2353527A (en) Adenosine A 3 receptor modulators
DK0861228T3 (da) Lipopolyaminer som transfektionsmidler samt deres farmaceutiske anvendelser
PE30891A1 (es) Composiciones y metodos terapeuticos sinergicos
TR200002191T2 (tr) Potasyum kanal önleyicileri
BR9814340A (pt) Derivados de indol como inibidores de fator xa
BR0110079A (pt) Combinação de compostos orgânicos
BR0011597A (pt) Método para separar compostos orgânicos análogos e resina de troca iÈnica
BRPI0518580A2 (pt) mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico
AR024138A1 (es) Inhibidores de la proliferacion celular
DK1297013T3 (da) Anvendelse af TACI som antitumormiddel
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
BRPI0309651B8 (pt) método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
DK0790246T3 (da) Middel til potensering af nervevækstfaktoraktivitet indeholdende 1,2-ethandiolderivat eller salt deraf
BR9908910A (pt) Sistema terapêutico transdérmico (tts) para a administração transcutânea de oxibutinina e método para sua preparação
NO20012817L (no) Fenetyl-5-brompyridyltiourea (PBT) og dihydroalkoksybenzyloksopyrimidin (DABO) derivater som utoverspermicidal aktivitet
NO20024231L (no) Lipidb¶rer
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
Rustenbeck et al. Polyamine modulation of mitochondrial calcium transport: II. Inhibition of mitochondrial permeability transition by aliphatic polyamines but not by aminoglucosides
IT1283110B1 (it) Composti a scheletro colchicinico,loro uso come farmaci e composizioni che li contengono
NO944214D0 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
BR9806193A (pt) Composição bi-aromáticos ligados por um radical heteroetinileno e composições farmacêuticas e cosméticas que os contêm

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2011026

Filing date: 20111214

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2011026

Filing date: 20111214

Extension date: 20240616

MK1K Patent expired
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2022019

Filing date: 20220603

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; REG. NO/DATE: EU/1/11/678 20220603

Spc suppl protection certif: 2022025

Filing date: 20220613

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317

Spc suppl protection certif: 2022019

Filing date: 20220603

Extension date: 20241216